PUBLIC COMPANY
saveOTSUKA
USupdated 6mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Estuary flows out of stealth with $103M to propel kidney disease gene therapies into clinicEstuary Biotherapeutics has swum out of stealth with $103 million in funding to power a pair of gene therapies into clinical trials for an inherited kidney disorder.fiercebiotech · 16d ago
- On the move: 4 rare disease companies hiring nowBiotechs developing therapeutics to treat rare diseases include two that received FDA approvals this year for drugs to treat spinal muscular atrophy and Alexander disease.biospace · 24d ago
- Lilly’s latest China drug deal; Immunovant’s setback in lupusLilly wagered up to $3.35 billion in its fourth China-focused alliance since January 2025. Elsewhere, analysts are now more confident about one of Vertex’s top prospects and an RNA drug succeeded a…biopharma_dive · 1mo ago
- Roche, Ionis RNA drug scores in kidney disease studyThe results position Roche to bring a new kind of medicine to market for IgA nephropathy, a disease that’s drawn considerable attention of late from drugmakers.biopharma_dive · 1mo ago
- Roche-Ionis’ RNA therapy reduces kidney disease marker, opening path to swift FDA nodA late-stage test of Roche and Ionis Pharmaceuticals’ sefaxersen showed that the drug reduced protein in the urine, which suggests the RNA-targeting therapy could improve kidney function and delay…biospace · 1mo ago
- Ionis-Otsuka offer 'groundbreaking' improvement in function and survival for genetic type of ALSUlefnersen, an RNA-targeted therapy being developed by Ionis Pharmaceuticals and Otsuka Pharmaceutical, improved measurements of functional impairment and survival in patients with a rare, genetic…biospace · 1mo ago
- Roche kidney drug's Phase 3 win sets up path to accelerated approvalRoche moves closer to entering an increasingly crowded kidney disease market where Novartis, Calliditas, Travere, Otsuka and Vera already have approved drugs. The Swiss pharma reported interim Phas…endpoints · 1mo ago
- Vertex opens up larger kidney disease opportunity with mid-stage readoutWhile Vertex is laser-focused on an upcoming FDA decision for povetacicept in immunoglobulin A nephropathy, the APOL1 inhibitor inaxaplin has demonstrated potential “best-in-class” data in a differ…biospace · 1mo ago
- Amgen's Phase 3 Sjögren's win; Novartis' $900M radioligand dealPlus news about Amgen, Novartis, Boomray, Merck's Winrevair, Lexeo and Mantle. Ionis and Otsuka tout Phase 3 win in specific type of ALS: Ionis said its Otsuka-partnered drug candidate, ulefnersen,endpoints · 1mo ago
- STAT+: Novo may be getting a better deal than expected with Medicare’s Bridge programEli Lilly and Novo Nordisk were already benefitting a great deal from the Trump administration's pilot program covering obesity drugs for seniors at a price of $245 a month. It…stat · 1mo ago
comments(0)
5-min edit window · permanent after that